Seeking Alpha

Evoke Pharma’s Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023

SOLANA BEACH, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma (EVOK), Inc. , a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an ...
Seeking Alpha

Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis ...

SOLANA BEACH, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an ...
Nasdaq

Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®

SOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an ...
Nasdaq

Evoke Pharma Secures Two New Patents For GIMOTI Nasal Spray, Expanding IP Portfolio

(RTTNews) - Evoke Pharma Inc. (EVOK), a pharmaceutical company focused on treatments for gastrointestinal diseases, announced on Tuesday that it has received notices of allowance for two additional ...
ksn.com

Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at ...

SOLANA BEACH, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an ...